Imagine leaving the hospital after suffering a heart attack without being treated for hypertension or being started on a beta blocker. What would we think of the hospital where patients are never educated about the relationship between treating hypertension and reducing myocardial infarction and stroke risk? Unfortunately, this happens every day with osteoporosis and fractures…
NEW YORK (Reuters Health)—Rates of osteoporotic fracture were similar three years after starting either denosumab or alendronate in a real-world Danish population-based cohort study. “Previous studies have shown that denosumab is more efficacious than alendronate in increasing bone mineral density (BMD), possibly the best proxy outcome for subsequent fracture risk. However, previous studies were underpowered…